Buchumschlag

Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Juan Macias, Mario Frias, Juan Antonio Pineda, Diana Corona‐Mata, Anais Corma‐Gomez, Antonio Rivero‐Juarez, Marta Santos, Miguel García‐Deltoro, Antonio Rivero, Carmen Ricart‐Olmos, Alejandro Gonzalez‐Serna, Luis Miguel Real
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
von: Juan Macias, et al.
Veröffentlicht: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
von: Rong‐Xiang Ng, et al.
Veröffentlicht: (2025)

Systematic Review: Incidence of Liver‐Related Events in People Living With Hepatitis Delta Virus
von: Laura E. Telep, et al.
Veröffentlicht: (2025)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
von: Kaleb Tesfai, et al.
Veröffentlicht: (2026)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
von: Luis Antonio Díaz, et al.
Veröffentlicht: (2025)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
von: Yu Shi, et al.
Veröffentlicht: (2025)

Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply
von: Kaleb Tesfai, et al.
Veröffentlicht: (2025)

Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
von: Luis Antonio Díaz, et al.
Veröffentlicht: (2025)

Subtype Differences in Major Adverse Liver Outcomes and Cardiovascular Events and Mortality in Steatotic Liver Disease: A UK Biobank Analysis
von: Takao Miwa, et al.
Veröffentlicht: (2026)

The Prevalence and Risk Factors for at‐Risk MASH and Advanced Liver Fibrosis in People With Metabolic Risk Factors in Primary Care
von: Leon A. Adams, et al.
Veröffentlicht: (2026)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2025)

Editorial: Patient Reported Outcomes Provide Insight Into Disease Severity for People Living With Primary Sclerosing Cholangitis
von: Aisha Alawi, et al.
Veröffentlicht: (2025)

Effect of Nucleos(t)ide Analogues Withdrawal on Survival Outcomes in Patients With Hepatitis B Virus‐Related Acute‐on‐Chronic Liver Failure
von: Yanxue Lin, et al.
Veröffentlicht: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol–Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment. Authors' Reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2025)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
von: Jee‐Fu Huang, et al.
Veröffentlicht: (2026)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2025)

Editorial: Effectiveness and safety of ustekinumab in ulcerative colitis—Where we are now in real life
von: Giammarco Mocci, et al.
Veröffentlicht: (2024)

Surviving Hepatitis C—Understanding Death and Survival Beyond Cure
von: Paul J. Clark, et al.
Veröffentlicht: (2025)

Editorial: Metabolic Dysfunction and Alcohol—Two Sides of the Same Coin
von: Gustavo Ayares, et al.
Veröffentlicht: (2024)

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
von: Pojsakorn Danpanichkul, et al.
Veröffentlicht: (2025)

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation
von: David Mehdi Asgher Niazi, et al.
Veröffentlicht: (2026)

Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States
von: Kelly Torosian, et al.
Veröffentlicht: (2025)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
von: Yee Hui Yeo, et al.
Veröffentlicht: (2026)

Waitlist and Post‐Transplant Outcomes in Liver Transplantation for Alcohol‐Associated Liver Disease: An Individual Patient Data Meta‐Analysis
von: Glenn Jun Kit Ho, et al.
Veröffentlicht: (2025)

Editorial: Balancing the Yin and Yang of Alcohol‐Associated Liver Disease—Integrating Pathophysiology, Liver‐Directed Therapy and Addiction Management
von: Raj Vuppalanchi, et al.
Veröffentlicht: (2025)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
von: Yi‐Ping Hung, et al.
Veröffentlicht: (2024)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions
von: Xinglin Li, et al.
Veröffentlicht: (2026)

Letter: Increased Prevalence of Visceral Obesity in Nonresponder Patients With Primary Biliary Cholangitis Based on Computed Tomography—Authors' Reply
von: Conrado Fernandez‐Rodriguez, et al.
Veröffentlicht: (2024)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease
von: Marco Vincenzo Lenti, et al.
Veröffentlicht: (2025)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2024)

Review article: Oesophageal disorders in chronic liver disease
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2024)

Editorial: The Role of Liver Biopsy in ANA Positive Subjects
von: Einar S. Björnsson
Veröffentlicht: (2026)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol
von: Karen Cheuk‐Ying Ho, et al.
Veröffentlicht: (2025)

Editorial: Cephalosporin‐Induced Liver Injury—Interesting but Tricky
von: Einar S. Björnsson
Veröffentlicht: (2025)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
von: Luis Calzadilla Bertot, et al.
Veröffentlicht: (2025)

The Emerging Short Chain Fatty Acid Enriched Metabotype in Irritable Bowel Syndrome and Its Potential Clinical Relevance
von: T. E. Conley, et al.
Veröffentlicht: (2026)

Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021
von: Chunlong Liu, et al.
Veröffentlicht: (2025)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
von: Ryan Yanzhe Lim, et al.
Veröffentlicht: (2026)

Letter: The multifaceted role of Escherichia coli in influencing disorders of industrial populations
von: Maria Rosa Ingrosso, et al.
Veröffentlicht: (2024)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
von: Muhammad Osama, et al.
Veröffentlicht: (2024)